Under the latest PDUFA, the FDA has five new criteria for choosing facilities to inspect – are you more likely to be inspected? Do your plans for dealing with drug shortages satisfy the new PDUFA requirements? How about your supplier quality agreements? Your facility registration? Your fast-track NDA? Your . . .
It would take weeks to read and digest the regulatory changes drugmakers face under the new PDUFA law — changes that may upend the way you do business. With some of the changes going into effect this year, you won’t want to wait that long.
Every five years, Congress reauthorizes the PDUFA law. In doing so, it not only raises the user fees drugmakers pay the FDA, it also lays out a long list of marching orders for the agency. The list includes:
- Changes to the requirements for registration of domestic and foreign drug establishments and commercial importers
- Direction to FDA to allocate inspection funding toward registered sites with “known safety risks”
- A mandate for early drugmaker notification on manufacturing changes that could create drug shortages
- Changes to FDA’s Accelerated Approval program
- A broadened definition of current good manufacturing practices (cGMP)that will give the agency greater control over a company’s suppliers.
- Enhanced counterfeiting penalties and fines
- Changes to 180-day exclusivity for generics first filers
- Mandates for electronic submissions of INDs, NDAs, BLAs and ANDAs
- New rules expanding accelerated approvals programs for new drugs
- Changes to the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act to encourage testing of medicines in children
- Addition of incentives for manufacturing new antibiotics (GAIN Act)
- Requirement of an FDA guidance on the promotion of drugs through social media within two years of the bill’s enactment; and
- Requirement that the FDA develop a strategy and implementation plan for advancing regulatory science.
- And more.
Don’t waste countless hours researching all the changes PDUFA has in store for your business. We’ve done the work for you with PDUFA V: A Drugmaker’s Guide to Provisions in the New Law.
PDUFA V: A Drugmaker’s Guide to Provisions in the New Law is available in print or PDF format for $377 each.
There's no risk when you purchase from FDAnews with our money-back guarantee. Not satisfied with your publication? Return the hard copy within 30
days (in resalable condition), and we will refund 100 percent of your purchase price (less shipping/handling). For the PDF version, you must notify FDAnews within
24 hours of receipt of purchase to receive a refund.
Interested in purchasing more than one print copy?
Significant volume discounts are available for ordering three or more
copies of the same book. You must order them at the same time and
provide a single payment to take advantage of the discount. Order below by clicking submit and then change your quantity in the shopping cart.
The discount will be calculated automatically.
3-4 copies – 10%
5-6 copies – 15%
7-9 copies – 20%
10+ copies – 25%
Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally with any questions.
Interested in Electronic Multi-user Access?
For more information please contact Customer Service:
Save money with a license agreement allowing significant numbers of users access to an electronic version of this book. For multi-user access to multiple titles, FDAnews offers the Electronic Books Library – a personalized collection of FDAnews publications that is fully searchable.
Phone: +1 (703) 538-7600 or toll free (888) 838-5578